Lack of association of OPRM1 genotype and smoking cessation

Nicotine and Tobacco Research

Volumn 15, Issue 3, 2013, Pages 739-744

  Munafò, Marcus R ^a   Johnstone, Elaine C ^b   Aveyard, Paul ^c   Marteau, Theresa ^d  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MU OPIATE RECEPTOR;

ADULT; ALLELE; ARTICLE; FEMALE; GENERAL PRACTITIONER; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; UNITED KINGDOM;

ADULT; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GREAT BRITAIN; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NICOTINE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, MU; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84874053765     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nts174     Document Type: Article

References (25)

1. Becker, A., Grecksch, G., Kraus, J., Loh, H. H., Schroeder, H., & Höllt, V. (2002). Rewarding effects of ethanol and cocaine in μ opioid receptor-deficient mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 365(4), 296-302. doi:10.1007/ s00210-002-0533-2
2. Befort, K., Filliol, D., Décaillot, F. M., Gavériaux-Ruff, C., Hoehe, M. R., & Kieffer, B. L. (2001). A single nucleotide polymorphic mutation in the human μ-opioid receptor severely impairs receptor signaling. Journal of Biological Chemistry, 276(5), 3130-3137. doi:10.1074/jbc. M006352200
3. Berrendero, F., Kieffer, B. L., & Maldonado, R. (2002). Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice. Journal of Neuroscience, 22(24), 10935-10940. doi:0270-6474/02/2210935-06$15.00/0
4. Beyer, A., Koch, T., Schröder, H., Schulz, S., & Höllt, V. (2004). Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human μ-opioid receptor. Journal of Neurochemistry, 89(3), 553-560. doi:10.1111/j.1471-4159.2004.02340.x
5. Bond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L.,... Yu, L. (1998). Single-nucleotide polymorphism in the human μ opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the United States of America, 95(16), 9608- 9613. doi:10.1073/pnas.95.16.9608
6. Boyadjieva, N. I., & Sarkar, D. K. (1997). The secretory response of hypothalamic β-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sciences, 61(6), Pl59-Pl66. Retrieved from www.elsevier.com/locate/lifescie
7. Contarino, A., Picetti, R., Matthes, H. W., Koob, G. F., Kieffer, B. L., & Gold, L. H. (2002). Lack of reward and locomotor stimulation induced by heroin in μ-opioid receptor-deficient mice. European Journal of Pharmacology, 446(1-3), 103- 109. doi: 10.1016/S0014-2999(02)01812-5
8. Davenport, K. E., Houdi, A. A., & Vanloon, G. R. (1990). Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine: Evidence for nicotine-induced release of endogenous opioids in brain. Neuroscience Letters, 113(1), 40-46. Retrieved from www.elsevier. com/locate/neulet
9. Gianoulakis, C. (2001). Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. Journal of Psychiatry and Neuroscience, 26(4), 304-318. Retrieved from www.cma.ca/index.php/ci_ id/12267/la_id/1.htm
10. Hall, F. S., Goeb, M., Li, X. F., Sora, I., & Uhl, G. R. (2004). μ-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Molecular Brain Research, 121(1-2), 123-130. doi:10.1016/j. molbrainres.2003.10.024
11. Hall, F. S., Sora, I., & Uhl, G. R. (2001). Ethanol consumption and reward are decreased in μ-opiate receptor knockout mice. Psychopharmacology (Berlin), 154(1), 43-49. Retrieved from www.springer.com/biomed/neuroscience/journal/213
12. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86(9), 1119-1127. doi:10.1111/j.1360-0443.1991.tb01879.x
13. Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J., Restine, S.,... Berrettini, W. H. (2004). The functional μ opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. The Pharmacogenomics Journal, 4(3), 184-192. doi:10.1038/sj.tpj.6500238
14. Marteau, T. M., Aveyard, P., Munafò, M. R., Prevost, A. T., Hollands, G. J., Armstrong, D.,... Kinmonth, A. L. (2012). Effect on adherence to nicotine replacement therapy of informing smokers their dose is determined by their genotype: A randomised controlled trial. PLoS ONE, 7(4), e35249. doi:10.1371/journal.pone.0035249
15. Marteau, T. M., Munafò, M. R., Aveyard, P., Hill, C., Whitwell, S., Willis, T. A.,... Kinmonth, A. L. (2011). Trial protocol: Using genotype to tailor prescribing of nicotine replacement therapy: A randomised controlled trial assessing impact of communication upon adherence. BMC Public Health, 10, 680. doi: 10.1186/1471-2458-10-680
16. Munafò, M. R., Elliot, K. M., Murphy, M. F., Walton, R. T., & Johnstone, E. C. (2007). Association of the μ-opioid receptor gene with smoking cessation. The Pharmacogenomics Journal, 7(5), 353-361. doi:10.1038/sj.tpj.6500432
17. Munafò, M. R., Lerman, C., Niaura, R., Shields, A. E., & Swan, G. E. (2005). Smoking cessation treatment: Pharmacogenetic assessment. Current Opinion in Molecular Therapeutics, 7(3), 202-208. Retrieved from www.biomedcentral.com/ curropinmolther/
18. Munafò, M. R., Shields, A. E., Berrettini, W. H., Patterson, F., & Lerman, C. (2005). Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics, 6(3), 211-223. doi: 10.1517/14622416.6.3.211
19. Ray, R., Jepson, C., Wileyto, E. P., Dahl, J. P., Patterson, F., Rukstalis, M.,... Lerman, C. (2007). Genetic variation in μ-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine & Tobacco Research, 9(11), 1237-1241. doi:10.1080/14622200701648367
20. Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews (1): CD000146. doi: 10.1002/14651858.CD000146.pub3
21. Sullivan, P. F., Neale, B. M., van den Oord, E., Miles, M. F., Neale, M. C., Bulik, C. M.,... Kendler, K. S. (2004). Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 126B(1), 23-36. doi:10.1002/ajmg.b.20138
22. Tobacco and Genetics Consortium. (2010). Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nature Genetics, 42(5), 441-447. doi:10.1038/ng.571
23. Yuferov, V., Levran, O., Proudnikov, D., Nielsen, D. A., & Kreek, M. J. (2010). Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Annals of the New York Academy of Sciences, 1187, 184-207. doi:10.1111/ j.1749-6632.2009.05275.x
24. Zhang, L., Kendler, K. S., & Chen, X. N. (2006). The μ-opioid receptor gene and smoking initiation and nicotine dependence. Behavioral and Brain Functions, 2, 28. doi:10.1186/ 1744-9081-2-28
25. Zhang, Y., Wang, D. X., Johnson, A. D., Papp, A. C., & Sadee, W. (2005). Allelic expression imbalance of human μ opioid receptor (OPRM1) caused by variant A118G. Journal of Biological Chemistry, 280(38), 32618-32624. doi:10.1074/ jbc.M504942200